These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Skin-resident memory T cells as a potential new therapeutic target in vitiligo and melanoma. Willemsen M; Linkutė R; Luiten RM; Matos TR Pigment Cell Melanoma Res; 2019 Sep; 32(5):612-622. PubMed ID: 31230406 [TBL] [Abstract][Full Text] [Related]
4. Differential Expression of CD49a and CD49b Determines Localization and Function of Tumor-Infiltrating CD8 Melssen MM; Lindsay RS; Stasiak K; Rodriguez AB; Briegel AM; Cyranowski S; Rutkowski MR; Conaway MR; Melief CJM; van der Burg SH; Eyo U; Slingluff CL; Engelhard VH Cancer Immunol Res; 2021 May; 9(5):583-597. PubMed ID: 33619119 [TBL] [Abstract][Full Text] [Related]
5. Nivolumab Therapy for Treatment-Related Vitiligo in a Patient With Relapsed Metastatic Melanoma. Nakamura Y; Teramoto Y; Asami Y; Matsuya T; Adachi JI; Nishikawa R; Yamamoto A JAMA Dermatol; 2017 Sep; 153(9):942-944. PubMed ID: 28678991 [No Abstract] [Full Text] [Related]
6. Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports. Yoshino K; Nakayama T; Ito A; Sato E; Kitano S BMC Cancer; 2019 Oct; 19(1):1019. PubMed ID: 31664934 [TBL] [Abstract][Full Text] [Related]
11. The Role of Memory CD8 Riding RL; Harris JE J Immunol; 2019 Jul; 203(1):11-19. PubMed ID: 31209143 [TBL] [Abstract][Full Text] [Related]
12. Combined radiotherapy with nivolumab for extracranial metastatic malignant melanoma. Komatsu T; Konishi K; Aoshima M; Tokura Y; Nakamura K Jpn J Radiol; 2018 Dec; 36(12):712-718. PubMed ID: 30206802 [TBL] [Abstract][Full Text] [Related]
13. Melanocyte-specific CD49a Yokoi K; Watanabe R; Kume M; Yamane S; Tanaka A; Fujimoto M; Tanemura A J Dermatol; 2023 May; 50(5):710-714. PubMed ID: 36514908 [TBL] [Abstract][Full Text] [Related]
14. An unusual skin reaction in uveal melanoma during treatment with nivolumab: extragenital lichen sclerosus. Veronesi G; Scarfì F; Misciali C; Tartari F; Melotti B; Patrizi A; Dika E Anticancer Drugs; 2019 Oct; 30(9):969-972. PubMed ID: 31205068 [TBL] [Abstract][Full Text] [Related]
15. Treatment of a patient with HIV and metastatic melanoma with consequitive ipilimumab and nivolumab. Tomsitz D; Hein R; Biedermann T; Kohlmeyer J J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):e26-e28. PubMed ID: 28662283 [No Abstract] [Full Text] [Related]
16. Dermoscopic changes in malignant melanoma after successful treatment with nivolumab: A case report. Yamamura K; Otsuka A; Kaku Y; Seidel JA; Nomura M; Nagai H; Matsumoto S; Kabashima K J Dermatol; 2017 May; 44(5):547-548. PubMed ID: 27461159 [No Abstract] [Full Text] [Related]
17. Direct evidence to support the role of antigen-specific CD8(+) T cells in melanoma-associated vitiligo. Le Gal FA; Avril MF; Bosq J; Lefebvre P; Deschemin JC; Andrieu M; Dore MX; Guillet JG J Invest Dermatol; 2001 Dec; 117(6):1464-70. PubMed ID: 11886510 [TBL] [Abstract][Full Text] [Related]
19. Profile fluctuation of peripheral blood in advanced melanoma patients treated with nivolumab. Saito R; Sawada Y; Saito-Sasaki N; Yamamoto K; Yoshioka H; Ohmori S; Yoshioka M; Okada E; Nakamura M J Dermatol; 2018 Dec; 45(12):1452-1455. PubMed ID: 30204257 [TBL] [Abstract][Full Text] [Related]
20. Age-associated changes in the immune system may influence the response to anti-PD1 therapy in metastatic melanoma patients. Kasanen H; Hernberg M; Mäkelä S; Brück O; Juteau S; Kohtamäki L; Ilander M; Mustjoki S; Kreutzman A Cancer Immunol Immunother; 2020 May; 69(5):717-730. PubMed ID: 32036449 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]